Inactive Instrument

Bausch Health Companies Inc Stock Nyse

CA91911K1021

Chart Bausch Health Companies Inc

Duration

Period

Style

Dynamic Chart

Latest news about Bausch Health Companies Inc

Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says	Apr. 12	MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds	Apr. 12	MT
Bausch wins US appeal to block Alvogen generic of diarrhea drug	Apr. 11	RE
Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan	Apr. 11	CI
TSX ends flat as gold stocks drop, mood cautious ahead of rate decision	Apr. 08	RE
Bausch Health Up Near 0.4% In US Premarket After Announcing Patent Lawsuit Against Amneal Pharmaceuticals	Apr. 08	MT
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
Trump eyes $43 million haul from biggest fundraiser yet	Apr. 06	RE
RBC Raises Bausch Health Target to US$12, Maintains Sector Perform, on Upcoming Xifaxan Litigation Ruling	Apr. 05	MT
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating	Apr. 05	MT
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for Uceris Aerosol Foam	Apr. 03	MT
Bausch Health Brief: Bausch Health, Canada Inc. Announcing First Public Drug Plan Listings for UCERIS Aerosol Foam	Apr. 03	MT
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults	Apr. 03	CI
Trump can't match Biden's 2024 fundraising, Republican's campaign says	Mar. 28	RE
Bausch + Lomb to Present New Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting	Mar. 27	MT

More news

Latest transcript on Bausch Health Companies Inc

Bausch Health Companies Inc., Q4 2023 Earnings Call, Feb 22, 2024

Feb. 22

More transcripts

Analyst Recommendations on Bausch Health Companies Inc

Trump eyes $43 million haul from biggest fundraiser yet	Apr. 06	RE
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating	Apr. 05	MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Keeps Sector Perform Rating	Feb. 23	MT
North American Morning Briefing : Mood Lifted on Hopes Rate-Hike Cycle Has Peaked	Nov. 02	DJ
RBC Cuts Price Target on Bausch Health to $8 From $9 Ahead of Q3 Report, Keeps Sector Perform Rating	23-10-23	MT

More recommendations

Press releases Bausch Health Companies Inc

Bausch Health, Canada Inc. - Acne vulgaris treatment PrARAZLO now available to patients through British Columbia PharmaCare public drug plan	Apr. 12	AQ
Bausch Health Companies - Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich's Abbreviated New Drug Application Until 2029	Apr. 12	AQ
Bausch Health to Announce First-Quarter 2024 Results on May 2	Apr. 12	AQ
Canadian Investment Regulatory Organization Trade Resumption - BHC	Apr. 11	AQ
Canadian Investment Regulatory Organization Trading Halt - BHC	Apr. 11	AQ

More press releases

News in other languages on Bausch Health Companies Inc

Insider - Milliardäre sammelten Geld für Trumps Sicherheitsleistung	Mar. 26
Bausch Health Companies Inc.: KORREKTUR DURCH QUELLE: Thermage(R) FLX und TR-4 Return Pad von Solta Medical erhalten Registrierungszertifikate in China	Jan. 18
KKR : signe un accord de financement avec Bausch Health	23-07-10
Citadel : l'hedge da record, 16 miliardi di dollari di utili (MF)	23-01-24
Bolsa de Madrid: ¿Culpa o no culpa?	22-06-17

More news

Managers and Directors - Bausch Health Companies Inc

Managers	Title	Age	Since
Thomas Appio CEO	Chief Executive Officer	61	-
John Barresi DFI	Director of Finance/CFO	51	22-05-23
Mirza Dautbegovic COO	Chief Operating Officer	-	-

Members of the board	Title	Age	Since
Robert Power BRD	Director/Board Member	67	08-07-31
John Paulson CHM	Chairman	68	17-05-31
Steven Miller BRD	Director/Board Member	35	21-03-16

More insiders

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.

Sector

Pharmaceuticals

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+28.66%	676B
NOVO NORDISK A/S	+23.58%	554B
JOHNSON & JOHNSON	-7.71%	349B
MERCK & CO., INC.	+14.65%	318B
ABBVIE INC.	+6.98%	291B
ASTRAZENECA PLC	+2.96%	210B
NOVARTIS AG	-0.41%	204B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-12.07%	144B

Other Pharmaceuticals

Sales 2024 *	9.39B	Sales 2025 *	9.4B	Capitalization	3.18B
Net income 2024 *	218M	Net income 2025 *	416M	EV / Sales 2024 *	2.46 x
Net Debt 2024 *	19.91B	Net Debt 2025 *	18.33B	EV / Sales 2025 *	2.29 x
P/E ratio 2024 *	13.9 x	P/E ratio 2025 *	7.73 x	Employees	-
Yield 2024 *	-	Yield 2025 *	-	Free-Float	97.66%